A pilot study of intra-arterial carboplatin in patients with recurrent carcinoma of the cervix, postradiation.
Twelve patients with recurrent squamous cell carcinoma of the cervix restricted to the pelvis were treated with intra-arterial infusion of carboplatin. The initial carboplatin dose was 300 mg/m2, every 4 weeks, and the dose was escalated to 450 mg/m2. Myelosuppression was the dose-limiting toxicity at the 450 mg/m2 dose. One patient died of treatment-related febrile neutropenia at that dose level. Two patients having received one cycle at 300 mg/m2 suffered grade 3 peripheral paresthesia. There were no objective responses but five patients had a subjective improvement of pain and performance status.
Verma
S
S
Ottawa Regional Cancer Centre, Ontario, Canada.
Prefontaine
M
M
Bertrand
M
M
Genest
P
P
Dahrouge
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010865:Pilot Projects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*
D016190:Carboplatin